Enfortumab vedotin: Revision history

From IDWiki

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

2 October 2025

  • curprev 15:3215:32, 2 October 2025 Aidan talk contribs 604 bytes +604 Created page with "* Antibody-drug conjugate targeting Nectin-4 that is present on the surface of most urothelial cancer cells * Indicated for urothelial cancer * Common adverse effects include: rashes (about 50%, can be severe), alopecia (in about 50%); abdominal pain, anorexia, constipation, diarrhea, and nausea/vomiting; fatigue; myelosuppression; myalgias; dysgeusia; peripheral neuropathy (in about 50%, can be severe); dry eyes ** Also liver enzyme abnormalities, insomnia, hypergly..." Tag: Visual edit
Retrieved from "https://idwiki.org/Enfortumab_vedotin"
Powered by MediaWiki
Powered by Semantic MediaWiki